NASDAQ
4.74USD
+0.38 (+8.72%)
We have scored 11 news catalysts on BioStem Technologies, Inc. (BSEM) over the past 12 months. The biggest single-day move next to one of them came Jan 21, 2026, when BSEM closed +22.1%: “BioStem Technologies Advances Entry into the Acute Wound Care Market with Acquisition of BioTissue Holdings' Surgical and Wound Care Business”. Coverage across the window leans positive (average ticker sentiment +0.31). Most of the impact sits in short squeeze potential and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
80.5M
P/E
—
EPS
—
Beta
0.26
52W range
2.251-8.4
Day range
4.24–5.35
Open
4.25
Prev close
4.36
Volume
857.1K
Avg volume
89.3K
Dividend
0.00
IPO
2015-03-17
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about BioStem Technologies, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for BSEM: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
